AGEN
AGENUS INC
NASDAQ · Healthcare · Biotechnology · US
$6.97
+4.50%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$6.98
From 52W high−29.81%
Volume729883.00
Market cap$314.78M
P/E (TTM)2.6x
P/S (TTM)2.4x
Div yield—
Key dataNov 4, 2026
Open
$6.98
From 52W high
−29.81%
Volume
729883.00
Market cap
$314.78M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
2.1x
P/E (TTM)
2.6x
RSI (14)
48.7
MomentumView details →
1D Return
+4.50%
YTD Return
+120.38%
SummaryUpdated Jun 1, 2026
Agenus Inc. (NASDAQ:AGEN) is a clinical-stage immuno-oncology biotechnology company founded in 1994 and headquartered in Lexington, Massachusetts. Originally incorporated as Antigenics Inc., the company changed its name to Agenus in January 2011. Agenus focuses on discovering and developing innovative cancer immunotherapies, with its lead program being the combination therapy of botensilimab and balstilimab (BOT/BAL) showing promising results in treating various solid tumors, particularly colorectal cancer. The company went public in February 2000 and has built a comprehensive pipeline of immuno-oncology treatments while also developing proprietary antibody discovery platforms.
Similar companies
Latest newsMore news →
AGENUS INC announced early Phase 2 NEOASIS results showing that 72% of patients with locally advanced dMMR colon cancer had no cancer remaining at surgery after six weeks of botensilimab plus balstilimab.11d agoArmenia’s Ministry of Health granted marketing authorizations for Agenus’ Botvymo (botensilimab) and Evamplix (balstilimab), approved in combination to treat adults with previously treated MSS metastatic colorectal cancer without active liver metastases.28d agoAgenus Inc. announced three-year follow-up results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating botensilimab plus balstilimab, reporting 48% estimated three-year survival, at IGCS 2026.32d ago